The group is working on the molecular pathogenesis, diagnosis and therapy of myeloid leukemia with a focus on chronic myelogenous leukemia (CML) and related myeloproliferative (MPN) and myelodysplastic (MDS) diseases. In close connection between the clinic and the laboratory, several translational research projects in the fields of molecular genetics, epigenetics, clonal evolution and aging are being worked on. Using state-of-the-art sequencing techniques (pyrosequencing, next-generation sequencing) and array technology, genome-wide studies of genetic and epigenetic alterations are performed and functionally characterized in the cell model. The data obtained are analyzed and correlated with clinical parameters (e.g., response to therapy and disease progression). As a result, new prognostic markers and molecular targets can be identified, which could help to develop new targeted therapies for affected patients.